^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD20 overexpression

i
Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
Entrez ID:
Related biomarkers:
1year
Computational and Experimental Evaluation of Linker Peptides and Thioredoxin Fusion Tag in CD20-rituximab Specific Interactions. (PubMed, Iran J Pharm Res)
Experimental in vitro studies confirmed the computationally calculated affinity of rituximab towards the two designed CD20 constructs. Also, the cell-based binding assessment of anti-CD20 mAbs could be substituted by the engineered extracellular domain of human CD20 protein.
Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression • CD20 overexpression
|
Rituxan (rituximab)
1year
Prognostic Role of CD200 in Acute Lymphoblastic Leukemia Patients. (PubMed, Diagnostics (Basel))
This study showed that CD200 expression was expressed in 100% of the patients. Correlations between CD200 expression and different laboratory data of patients revealed that there was an impact of CD200 on different diagnostic findings. After the follow-up of the patients, we found that the use of PRISM function of the software could add value to the detection of minimal residual disease.
Journal
|
CD200 (CD200 Molecule)
|
CD20 expression • CD20 overexpression • CD200 expression
almost2years
FULL SPECTRAL FLOW CYTOMETRY ANALYSIS OF THE BONE MARROW IMMUNE MICROENVIRONMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME (EHA 2022)
The overexpression of CD200 on CD56dim natural killer (NK) cells was an independent risk factor for MDS. Conclusion The percentage of immune cells and expression of immune checkpoint proteins on immune cells from BMs of MDS were distinct from that of healthy control samples.
Clinical
|
CD200 (CD200 Molecule)
|
CD20 expression • CD20 overexpression • CD200 expression
2years
Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy. (PubMed, Sci Rep)
Finally, we reported the use of a novel strategy for the generation of anti-CD20 mAbs, with human and canine cross-reactivity, by exploring our rabbit derived single-domain antibody platform. Overall, these results support the rationale of using CD20 as a target for veterinary settings and the development of novel therapeutics and immunodiagnostics.
Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 overexpression • CD2 overexpression
over2years
Journal
|
CD200 (CD200 Molecule)
|
CD20 expression • CD20 overexpression • CD200 expression
over2years
Follicular Lymphoma Microenvironment Signatures Define Patients Subsets Obtaining Long Term Clinical Benefit after Single-Agent First-Line Anti-CD20 Immunotherapy (ASH 2021)
The results here reported indicate that pts with a favorable immune signature could derive maximal benefit from a first-line chemo-free treatment approach with single agent Rituximab, achieving and maintaining complete remission in the long term, irrespective of the tumor burden and other clinical variables. Thus, profiling of FL microenvironment with T-GEP could provide a useful tool for selecting patients who may be suitable for a chemo-free upfront treatment with anti CD20 immunotherapy.
Clinical • IO biomarker
|
CCL19 (C-C Motif Chemokine Ligand 19) • CCL2 (Chemokine (C-C motif) ligand 2) • TNFRSF4 (TNF Receptor Superfamily Member 4) • IL17A (Interleukin 17A) • CCL22 (C-C Motif Chemokine Ligand 22) • IL17RB (Interleukin 17 Receptor B)
|
CD20 expression • CD20 overexpression • CCL19 overexpression • 6-gene signature
|
Rituxan (rituximab)
over2years
CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2 (ASH 2021)
Conclusion Our study shows that anti-MM cytotoxicity from primary healthy donor CD3+ T cells is attenuated by CD200 expression on MM cells. We also demonstrate that this inhibitory mechanism in CD3+ T cells is mediated via DOK2, providing a potential target for immunotherapeutic approaches in MM.
IO biomarker
|
CD200 (CD200 Molecule)
|
CD20 expression • CD20 overexpression • CD2 overexpression • CD200 expression
over2years
Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML. (PubMed, J Immunother Cancer)
Overexpression of CD200 is a stem cell-specific marker that contributes to immunosuppression in AML by impairing effector cell metabolism and function. CD200 antibody therapy is capable of simultaneously reducing CD200-mediated suppression while also engaging macrophage activity. This study lays the groundwork for CD200-targeted therapeutic strategies to eliminate LSCs and prevent AML relapse.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD200 (CD200 Molecule)
|
CD20 expression • CD20 overexpression • CD200 expression
|
Venclexta (venetoclax) • azacitidine